Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury

Ashish K. Sharma, Victor E. Laubach, Susan I. Ramos, Yunge Zhao, George Stukenborg, Joel Linden, Irving L. Kron, Zequan Yang

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Objective: Adenosine A2A receptor activation potently attenuates lung ischemia-reperfusion injury. This study tests the hypothesis that adenosine A2A receptor activation attenuates ischemia-reperfusion injury by inhibiting CD4+ T cell activation and subsequent neutrophil infiltration. Methods: An in vivo model of lung ischemia-reperfusion injury was used. C57BL/6 mice were assigned to either sham group (left thoracotomy) or 7 study groups that underwent ischemia-reperfusion (1 hour of left hilar occlusion plus 2 hours of reperfusion). ATL313, a selective adenosine A2A receptor agonist, was administered 5 minutes before reperfusion with or without antibody depletion of neutrophils or CD4+ T cells. After reperfusion, the following was measured: pulmonary function using an isolated, buffer-perfused lung system, T cell infiltration by immunohistochemistry, myeloperoxidase and proinflammatory cytokine/chemokine levels in bronchoalveolar lavage fluid, lung wet/dry weight, and microvascular permeability. Results: ATL313 significantly improved pulmonary function and reduced edema and microvascular permeability after ischemia-reperfusion compared with control. Immunohistochemistry and myeloperoxidase content demonstrated significantly reduced infiltration of neutrophils and CD4+ T cells after ischemia-reperfusion in ATL313-treated mice. Although CD4+ T cell-depleted and neutrophil-depleted mice displayed significantly reduced lung injury, no additional protection occurred when ATL313 was administered to these mice. Expression of tumor necrosis factor-α, interleukin 17, KC, monocyte chemotactic protein-1, macrophage inflammatory protein-1, and RANTES were significantly reduced in neutrophil- and CD4+ T cell-depleted mice and reduced further by ATL313 only in neutrophil-depleted mice. Conclusions: These results demonstrate that CD4+ T cells play a key role in mediating lung inflammation after ischemia-reperfusion. ATL313 likely exerts its protective effect largely through activation of adenosine A2A receptors on CD4+ T cells and neutrophils.

Original languageEnglish (US)
Pages (from-to)474-482
Number of pages9
JournalJournal of Thoracic and Cardiovascular Surgery
Volume139
Issue number2
DOIs
StatePublished - Feb 1 2010
Externally publishedYes

Fingerprint

Adenosine A2A Receptors
Reperfusion Injury
Neutrophils
Reperfusion
T-Lymphocytes
Lung
Ischemia
Neutrophil Infiltration
Capillary Permeability
Peroxidase
Adenosine A2 Receptor Agonists
Immunohistochemistry
Macrophage Inflammatory Proteins
Chemokine CCL5
Interleukin-17
Chemokine CCL2
Bronchoalveolar Lavage Fluid
Lung Injury
Pulmonary Edema
Thoracotomy

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury. / Sharma, Ashish K.; Laubach, Victor E.; Ramos, Susan I.; Zhao, Yunge; Stukenborg, George; Linden, Joel; Kron, Irving L.; Yang, Zequan.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 139, No. 2, 01.02.2010, p. 474-482.

Research output: Contribution to journalArticle

Sharma, Ashish K. ; Laubach, Victor E. ; Ramos, Susan I. ; Zhao, Yunge ; Stukenborg, George ; Linden, Joel ; Kron, Irving L. ; Yang, Zequan. / Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury. In: Journal of Thoracic and Cardiovascular Surgery. 2010 ; Vol. 139, No. 2. pp. 474-482.
@article{22f037acfdf24409828492b6ed4c3747,
title = "Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury",
abstract = "Objective: Adenosine A2A receptor activation potently attenuates lung ischemia-reperfusion injury. This study tests the hypothesis that adenosine A2A receptor activation attenuates ischemia-reperfusion injury by inhibiting CD4+ T cell activation and subsequent neutrophil infiltration. Methods: An in vivo model of lung ischemia-reperfusion injury was used. C57BL/6 mice were assigned to either sham group (left thoracotomy) or 7 study groups that underwent ischemia-reperfusion (1 hour of left hilar occlusion plus 2 hours of reperfusion). ATL313, a selective adenosine A2A receptor agonist, was administered 5 minutes before reperfusion with or without antibody depletion of neutrophils or CD4+ T cells. After reperfusion, the following was measured: pulmonary function using an isolated, buffer-perfused lung system, T cell infiltration by immunohistochemistry, myeloperoxidase and proinflammatory cytokine/chemokine levels in bronchoalveolar lavage fluid, lung wet/dry weight, and microvascular permeability. Results: ATL313 significantly improved pulmonary function and reduced edema and microvascular permeability after ischemia-reperfusion compared with control. Immunohistochemistry and myeloperoxidase content demonstrated significantly reduced infiltration of neutrophils and CD4+ T cells after ischemia-reperfusion in ATL313-treated mice. Although CD4+ T cell-depleted and neutrophil-depleted mice displayed significantly reduced lung injury, no additional protection occurred when ATL313 was administered to these mice. Expression of tumor necrosis factor-α, interleukin 17, KC, monocyte chemotactic protein-1, macrophage inflammatory protein-1, and RANTES were significantly reduced in neutrophil- and CD4+ T cell-depleted mice and reduced further by ATL313 only in neutrophil-depleted mice. Conclusions: These results demonstrate that CD4+ T cells play a key role in mediating lung inflammation after ischemia-reperfusion. ATL313 likely exerts its protective effect largely through activation of adenosine A2A receptors on CD4+ T cells and neutrophils.",
author = "Sharma, {Ashish K.} and Laubach, {Victor E.} and Ramos, {Susan I.} and Yunge Zhao and George Stukenborg and Joel Linden and Kron, {Irving L.} and Zequan Yang",
year = "2010",
month = "2",
day = "1",
doi = "10.1016/j.jtcvs.2009.08.033",
language = "English (US)",
volume = "139",
pages = "474--482",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury

AU - Sharma, Ashish K.

AU - Laubach, Victor E.

AU - Ramos, Susan I.

AU - Zhao, Yunge

AU - Stukenborg, George

AU - Linden, Joel

AU - Kron, Irving L.

AU - Yang, Zequan

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Objective: Adenosine A2A receptor activation potently attenuates lung ischemia-reperfusion injury. This study tests the hypothesis that adenosine A2A receptor activation attenuates ischemia-reperfusion injury by inhibiting CD4+ T cell activation and subsequent neutrophil infiltration. Methods: An in vivo model of lung ischemia-reperfusion injury was used. C57BL/6 mice were assigned to either sham group (left thoracotomy) or 7 study groups that underwent ischemia-reperfusion (1 hour of left hilar occlusion plus 2 hours of reperfusion). ATL313, a selective adenosine A2A receptor agonist, was administered 5 minutes before reperfusion with or without antibody depletion of neutrophils or CD4+ T cells. After reperfusion, the following was measured: pulmonary function using an isolated, buffer-perfused lung system, T cell infiltration by immunohistochemistry, myeloperoxidase and proinflammatory cytokine/chemokine levels in bronchoalveolar lavage fluid, lung wet/dry weight, and microvascular permeability. Results: ATL313 significantly improved pulmonary function and reduced edema and microvascular permeability after ischemia-reperfusion compared with control. Immunohistochemistry and myeloperoxidase content demonstrated significantly reduced infiltration of neutrophils and CD4+ T cells after ischemia-reperfusion in ATL313-treated mice. Although CD4+ T cell-depleted and neutrophil-depleted mice displayed significantly reduced lung injury, no additional protection occurred when ATL313 was administered to these mice. Expression of tumor necrosis factor-α, interleukin 17, KC, monocyte chemotactic protein-1, macrophage inflammatory protein-1, and RANTES were significantly reduced in neutrophil- and CD4+ T cell-depleted mice and reduced further by ATL313 only in neutrophil-depleted mice. Conclusions: These results demonstrate that CD4+ T cells play a key role in mediating lung inflammation after ischemia-reperfusion. ATL313 likely exerts its protective effect largely through activation of adenosine A2A receptors on CD4+ T cells and neutrophils.

AB - Objective: Adenosine A2A receptor activation potently attenuates lung ischemia-reperfusion injury. This study tests the hypothesis that adenosine A2A receptor activation attenuates ischemia-reperfusion injury by inhibiting CD4+ T cell activation and subsequent neutrophil infiltration. Methods: An in vivo model of lung ischemia-reperfusion injury was used. C57BL/6 mice were assigned to either sham group (left thoracotomy) or 7 study groups that underwent ischemia-reperfusion (1 hour of left hilar occlusion plus 2 hours of reperfusion). ATL313, a selective adenosine A2A receptor agonist, was administered 5 minutes before reperfusion with or without antibody depletion of neutrophils or CD4+ T cells. After reperfusion, the following was measured: pulmonary function using an isolated, buffer-perfused lung system, T cell infiltration by immunohistochemistry, myeloperoxidase and proinflammatory cytokine/chemokine levels in bronchoalveolar lavage fluid, lung wet/dry weight, and microvascular permeability. Results: ATL313 significantly improved pulmonary function and reduced edema and microvascular permeability after ischemia-reperfusion compared with control. Immunohistochemistry and myeloperoxidase content demonstrated significantly reduced infiltration of neutrophils and CD4+ T cells after ischemia-reperfusion in ATL313-treated mice. Although CD4+ T cell-depleted and neutrophil-depleted mice displayed significantly reduced lung injury, no additional protection occurred when ATL313 was administered to these mice. Expression of tumor necrosis factor-α, interleukin 17, KC, monocyte chemotactic protein-1, macrophage inflammatory protein-1, and RANTES were significantly reduced in neutrophil- and CD4+ T cell-depleted mice and reduced further by ATL313 only in neutrophil-depleted mice. Conclusions: These results demonstrate that CD4+ T cells play a key role in mediating lung inflammation after ischemia-reperfusion. ATL313 likely exerts its protective effect largely through activation of adenosine A2A receptors on CD4+ T cells and neutrophils.

UR - http://www.scopus.com/inward/record.url?scp=74649085137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74649085137&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2009.08.033

DO - 10.1016/j.jtcvs.2009.08.033

M3 - Article

C2 - 19909990

AN - SCOPUS:74649085137

VL - 139

SP - 474

EP - 482

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 2

ER -